Introduction
Type 1 diabetes (T1D) is an autoimmune disease caused by the CD4 + and CD8 + T-cell mediated destruction of the pancreatic insulin-producing beta cells (1) . Beta-cell destruction leads to primary insulin deficiency which is treated by exogenous insulin therapy, but currently there is no cure. The pathogenesis of T1D has been well characterized in the NOD mouse model, but the immune basis of T1D in humans is less clear.
Genetic association studies have provided powerful insights into the etiology of human T1D (2; 3). The HLA class II region has the strongest impact on risk of T1D. Some HLA alleles, DQB1*06:02 for example, dominantly protect against T1D (4) . In contrast HLA-DQ2 (DQA*0501, DQB*0201) and DQ8 (DQ*A0301, DQB*0302) confer the greatest risk of developing T1D of any alleles (5) . Remarkably, individuals heterozygous for HLA-DQ2
and HLA-DQ8 are at greater risk of developing T1D than those with either HLA DQ2 or DQ8 alone (6) . The basis of this observation is unclear. However, HLA-DQ2; DQ8
heterozygous APC can form two extra functional HLA molecules: a DQ8transdimer composed of the DQ2α chain paired with the HLA-DQ8β chain (DQA*05:01; DQB*03:02) and similarly a DQ2 transdimer where the DQ8β pairs with DQ2α (DQA1*03:01; DQB1*02:01) (7) . These transdimers may promote beta-cell autoimmunity by presenting unique diabetogenic epitopes, or the high density of T1D-promoting HLA molecules (DQ2, DQ8, DQ2trans and DQ8trans) may promote autoimmune CD4 + T-cell responses against beta-cell antigens (7; 8) . Because the epitopes presented by HLA DQ2/8 transdimers have not been identified these possibilities remain speculative. Nonetheless, the function of HLA-DQ is to present antigens to CD4 + T cells, hence these genetic associations are strong evidence that CD4 + T-cell responses against beta-cell antigens play a pivotal role in the development of T1D in humans.
Since insulin specific autoantibodies were detected before the onset of T1D (9) insulin and its precursor proinsulin have been candidate autoantigens in T1D. It is now clear that T-cell responses to (pro)insulin are essential for the development of T1D in the NOD mouse (10 ; 11), but (pro)insulin's role in human T1D has not been confirmed. Genetic association studies have implicated proinsulin because a T1D susceptibility locus, IDDM2, maps to a variable number of tandem repeats (VNTR) upstream of the insulin gene (12; 13) . This polymorphism is believed to modulate proinsulin expression in the thymus affecting central tolerance (12) (13) (14) . This observation provides circumstantial evidence that proinsulin plays a crucial role as an autoantigen in T1D. Many studies have attempted to detect proinsulin specific CD4 + T-cell responses in the PBMC of T1D patients and healthy control subjects (15) . Using sensitive methods capable of detecting very rare T cells, some investigators could detect weak responses to proinsulin peptides (16). However, these CD4 + T cells could not be analyzed in detail. Furthermore, T cells isolated from the pancreatic lymph nodes of deceased organ donors who had T1D were reported to be insulin specific but HLA-DR4 restricted (17).
These genetic associations, between HLA and insulin alleles, predict that HLA-DQ2 and HLA-DQ8 restricted, proinsulin specific, CD4 + T cells will infiltrate human islets where they play a pathogenic role in T1D. However, while predicted, these CD4 + T cells have never been isolated from human islets leaving a crucial piece in the chain of autoimmune causation in T1D missing. This gap in our knowledge has lead some to question the autoimmune basis of human T1D (18; 19).
Here we show that CD4 + T cells isolated from within the islets of an organ donor who had T1D recognize proinsulin epitopes presented by HLA-DQ8, and HLA-DQ8-transdimers.
This work reveals how molecules implicated by genetic association studies; HLA-DQ8 and proinsulin, lead to autoimmune response against human beta cells and provides new evidence to support the notion that human T1D is an autoimmune disease.
Research Design and Methods

Ethical Approvals
The isolation of pancreatic islets from deceased organ donors was approved by the St.
Vincent's Hospital Human Research Ethics committee (approval number SVH HREC-A 011/04). Collection of peripheral blood samples from T1D patients was approved by Southern Health Human Research Ethics Committee-B (approval number 12185B).
Collection of blood from healthy donors was approved by St. Vincent's Hospital Human
Research Ethics committee (approval number SVH HREC-A 135/08).
Islet isolation
After obtaining informed consent from the next-of-kin, the pancreas was removed from heart beating, brain-dead donors by the Tom Mandel Islet Transplant Program. Islets were purified as previously described (20) by intraductal perfusion and digestion of the pancreas with collagenase followed by purification using Ficoll density gradients. Islet purity was assessed by light microscopy after staining with dithizone (Sigma Chemical, St. Louis, MO). Thirty thousand islet equivalents were isolated from the tail of the pancreas.
Approximately one thousand islets were cultured in CMRL overnight then stained to detect T cells by flow cytometry. All the remaining islets were cultured directly after isolation in 24-well plate in 1.0ml of RPMI/ 5% pooled human serum (PHS) containing IL-2 (20U/ml) and IL-15 (5ng/ml) for 7-10 days. After this time a halo of lymphocytes was visible surrounding 3-4 islets. Cells from wells containing growing T cells were collected and stained with anti-CD3-PerCP (UHCTI), and CD4-phycoerythrin (OKT4) and anti-CD8α-Alexa Fluor 647 (OKT8). Dead cells were excluded with propidium iodide staining. CD3 + , CD4 + cells were cloned by sorting a single CD4 + T cell into wells of a 96-well plate containing irradiated allogeneic PBMC, anti-CD3 and cytokines as described (21; 22).
After two-three weeks, growing clones were collected and subjected to another round of CD3-stimulated growth in the presences of IL-2 (20U/ml) and IL-4 (5ng/ml) as described (21; 22). This expansion yielded >100 million cloned CD4 + T cells in most cases. Aliquots of 5 million expanded T-cells were cryopreserved in 10% DMSO/FCS as described (23) and stored over liquid nitrogen until required.
Histology
Pancreas specimens from the head of the organ were taken before perfusion with collagenase and were snap frozen in OCT compound (Sakura Finetek, CA, USA) Frozen sections were fixed in acetone for 5 minutes at room temperature and then washed in PBS. 
HLA restriction
HLA restriction was determined in two steps as described previously (24-26). First monoclonal antibodies specific for HLA DR (clone L243), DP (clone B7/21) and DQ (clone SPV-L3) were added to the peptide stimulated T-cell cultures to a final concentration of 1-10 µg/ml. Second the HLA alleles were determined using a panel of T2 cells tranduced with a retrovirus encoding for the HLA-DQA and DQB alleles indicated in the figure legends.
TCR sequencing
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RNA was extracted from 1-2 million cloned T cells using an RNA extraction kit (Macherey Nagel, Duren, Germany) and converted to cDNA using Smartscribe Reverse Transcriptase (Clontech, Mountain View, Ca). TRA and TRB genes were amplified using pools of reverse primers using Taq polymerase (Invitrogen, Mulgrave Victoria Austalia) as described by Wang et al (27) . PCR product was sequenced and the TCR genes identified by alignment with the IMGT database (http://www.imgt.org/IMGT_vquest)(28).
Insulin VNTR genotyping
Genomic DNA was purified from 5 million cloned T cells using QIamp DNA Blood min kit (Qaigen, Hilden, Germany). Genotyping of the single nucleotide polymorphism, rs689 was performed using an inventoried Taqman SNP Genotyping Assay obtained from Applied Biosystems (Life Technologies, Carlsbad, California). The assay was run on a Roche LightCycler 480 II using Roche Probe Master Mix (Roche Applied Science, Penzberg, Germany) according to manufacturer's instructions.
CFSE proliferation assays
The CFSE (5,6-carboxylfluorescein diacetate succinimidyl ester) proliferation assays were performed as described previously (15; 22 
Results
To characterize human CD4 + T cell responses associated with T1D we obtained the pancreas from a deceased organ donor who suffered from T1D. The organ donor was diagnosed with type 1 diabetes at the age of 16 years. At diagnosis his blood glucose was 612mg/dL (34mmol/L, normal 4.0-6.0mmol/L) and C-peptide was 1.2ng/ml (0.4nmol/L).
He had autoantibodies to GAD-65 (glutamic acid decarboxylase) and IA-2 (tyrosine phosphatase-related islet antigen 2). He was treated with short (Insulin glulisine) and long- Fig 1A) . The infiltrate included CD4 + and CD8 + T-cells (Fig 1B) which was confirmed by flow cytometry (Fig 1D) . Thirty thousand islet equivalents were isolated, to >90% purity. After overnight culture in CMRL the islets were cultured in RPMI/PHS with IL-2 and IL-15.
After one week cells were visible around 3-4 islets (Fig 1C) . (Fig. 1F-H) . Fourteen of 53 clones (26.4%) responded to proinsulin peptides ( Supplementary Fig 1) , but none of the clones responded to any of the other epitopes tested (not shown). Clones that responded to the pool of 13 proinsulin peptides ( Fig 1F) were re-tested against each peptide separately. Ten clones, including 6.15, responded to proinsulin 37-54 (Fig. 1G ). The remaining clones responded to proinsulin 43-60, or proinsulin 49-66. Fine epitope mapping (Fig 1H) revealed that all 10
clones that responded to proinsulin 37-54 recognized the same core epitope (proinsulin 42-50, VELGGGPGA), but differences in their fine specificity were noted ( Table 2 , Supplementary Fig 2) . To examine the clonal diversity of the islet-infiltrating CD4 + T cells the T-cell receptor (TCR) genes expressed by the clones were sequenced. The clones used a range of TRAV and TRBV genes (Fig 3A, B) . The most frequently expressed TRAV gene was TRAV26-1, which was expressed by 7 of 53 clones (13%). In contrast TRBV gene usage was more skewed, TRBV5*01 was expressed by 16 of the clones (30%) (Fig 3A, B) . Translated TCR sequences for all clones are shown in supplementary Table 3 . No skewing of the CDR3 length was detected for TRAV and TRBV genes (Fig 3C, D) . In total 47 unique clonotypes were expressed. We identified three sets of sister clones with identical TCRs (Fig 3E) . The first set comprised four clones: 1.9, 2.1, 3.14 and 4.6. These clones all used TRAV 20*02; Analysis of the clone's antigen specificity showed that the clones isolated more than once all recognized proinsulin epitopes. Interestingly, the TCRβ chain, TRBV 5-1*01, was used by four of five clone families specific for epitopes falling in proinsulin 40-51. Three of four TRVB 5-1*01 expressing clones also expressed TRAV 26-1*01. Collectively, the 14 clones specific for proinsulin C-peptide epitopes used eight distinct TRA/TRB combinations ( Table 1) . Although several clones used the same TRAV and TRBV, there was no evidence of conserved amino acids in the CDR3 (Table 1 and Supplementary Table   3 ). This analysis revealed that several independent, proinsulin specific, clones infiltrated the islets of this donor.
Finally, we used a CFSE-based proliferation assay (29) The donor's homozygous type 1 insulin VNTR genotype may have promoted the broad Tcell response against proinsulin. HLA-DR4 restricted CD4 + T cells specific for proinsulin 52-66 were most frequently detected in the blood of subjects who were VNTR I homozygous (14) . Our analysis of the TCR genes expressed by human islet infiltrating CD4 + T cells revealed that the 53 clones expressed 47 unique clonotypes. We cannot exclude the possibility that the isolation of multiple clones with unique TCRs arose from skewing of the repertoire of infiltrating T-cells occurred while the islets were cultured in the presence of cytokines, rather than in vivo prior to islet isolation. Nonetheless, eight unique, proinsulin specific clonotypes were present, arguing against the possibility that proinsulin-specific CD4 + T cells were grossly favored during the isolation.
The T cells we isolated were not selected based on their antigen specificity, yet the epitopes recognized fall in a narrow region of the C-peptide of proinsulin. Several clones recognize epitopes containing the sequence -GGGPGA-(see Table 1 ) which is rich in amino acids with very small side chains. It remains to be determined if this very 'bland' epitope is recognized by CD4 + T cells with degenerate specificity as has been reported for proinsulin specific CD8 + T cells (31). This degenerate specificity may allow these proinsulin-reactive T cells to escape thymic deletion, yet become activated in the islets where the concentration of proinsulin is very high. The antigen specificity of many of the clones was not defined.
Most of these clones may respond to other, as yet undefined beta-cell antigens. It remains possible that the three clones that did not make IFNγ respond to some of the peptides tested here, but were not detected because they secrete cytokines other than IFNγ.
There have been very few previous reports of HLA-DQ8 restricted responses against betacell antigens (32). All fourteen T-cell clones reported in this study recognized proinsulin peptides presented by HLA-DQ8, or DQ8-transdimer. There was no evidence of a unique DQ8-transdimer restricted epitope, the DQ8-transdimer restricted epitope overlaps almost completely with two DQ8 restricted epitopes. Hence, these data support the hypothesis that HLA-DQ2; DQ8 heterozygous individuals are at greatest genetic risk of type 1 diabetes because they have a relatively high density of type 1 diabetes-associated HLA molecules on the surface of their antigen presenting cells. 
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